Vera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vera Therapeutics's estimated annual revenue is currently $5.7M per year.
- Vera Therapeutics's estimated revenue per employee is $77,500
- Vera Therapeutics's total funding is $188.9M.
Employee Data
- Vera Therapeutics has 74 Employees.
- Vera Therapeutics grew their employee count by 19% last year.
Vera Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | Chief Accounting Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | SVP and Head Biometrics | Reveal Email/Phone |
5 | SVP Medical Affairs | Reveal Email/Phone |
6 | SVP, Product Development and Manufacturing | Reveal Email/Phone |
7 | VP, Head Legal | Reveal Email/Phone |
8 | VP, Head Business Development and Alliance Management | Reveal Email/Phone |
9 | SVP, Development Operations | Reveal Email/Phone |
10 | SVP, Head Product Development and Manufacturing | Reveal Email/Phone |
Vera Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Vera Therapeutics?
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients' lives.
keywords:N/A
$188.9M
Total Funding
74
Number of Employees
$5.7M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vera Therapeutics News
Vera Therapeutics (NASDAQ:VERA Get Rating) is one of 937 publicly-traded companies in the Pharmaceutical preparations industry,...
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of Buy by Analysts. Posted by admin on Apr 19th, 2022.
Wedbush has a Outperform rating and a $32.00 price objective on the stock. Wedbush also issued estimates for Vera Therapeutics' Q2 2022...
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Celia Lin, MD, as ...
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 /PRNewswire/ -- Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. Ot ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.9M | 77 | 10% | N/A |
#2 | $23.5M | 77 | 12% | N/A |
#3 | $21.1M | 78 | 39% | N/A |
#4 | $10.1M | 78 | 0% | $5.9M |
#5 | $11.3M | 78 | -7% | N/A |